<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37302406</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.</ArticleTitle><Pagination><StartPage>1119</StartPage><EndPage>1129</EndPage><MedlinePgn>1119-1129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(23)00299-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(23)00299-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.</AbstractText><AbstractText Label="METHODS">We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30-85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2&#x2008;&#xd7;&#x2008;3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194.</AbstractText><AbstractText Label="FINDINGS">Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56&#xb7;1%) of 1126 participants were female and 494 (43&#xb7;9%) were male; 44 (7&#xb7;0%) of 632 women were pregnant. The median age was 45 years (IQR 37-54) and median BMI was 29&#xb7;8 kg/m<sup>2</sup> (IQR 27&#xb7;0-34&#xb7;2). Overall, 93 (8&#xb7;3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6&#xb7;3% (95% CI 4&#xb7;2-8&#xb7;2) in participants who received metformin and 10&#xb7;4% (7&#xb7;8-12&#xb7;9) in those who received identical metformin placebo (hazard ratio [HR] 0&#xb7;59, 95% CI 0&#xb7;39-0&#xb7;89; p=0&#xb7;012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0&#xb7;37 (95% CI 0&#xb7;15-0&#xb7;95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0&#xb7;99, 95% CI 0&#xb7;59-1&#xb7;64) or fluvoxamine (1&#xb7;36, 0&#xb7;78-2&#xb7;34) compared with placebo.</AbstractText><AbstractText Label="INTERPRETATION">Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4&#xb7;1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.</AbstractText><AbstractText Label="FUNDING">Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA. Electronic address: bramante@umn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Endocrinology, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Colorado, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UnitedHealth Group, Optum Labs, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Olive View, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullen</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Medicine, Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirtz</LastName><ForeName>Esteban Lemus</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lianne K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proper</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odde</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Nancy E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindberg</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckman</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Tanvi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Gwendolyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Neeta S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Medicine, Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-OUT Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04510194</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004406</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA210190</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL129956</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 LM012744</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL156812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-017069</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012982</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL133604</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002492</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA254849</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2023 Oct;23(10):1096-1097. doi: 10.1016/S1473-3099(23)00355-9</RefSource><PMID Version="1">37302405</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Infect Dis. 2023 Oct;23(10):e400. doi: 10.1016/S1473-3099(23)00562-5</RefSource><PMID Version="1">37666258</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests CTB was supported by grants (KL2TR002492 and UL1TR002494) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and by a grant (K23 DK124654&#x2013;01-A1) from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. JBB was supported by grants (UL1TR002489 and UM1TR004406) from NCATS and reports contracted fees and travel support for contracted activities for consulting work paid to the University of North Carolina by Novo Nordisk; grant support by Dexcom, NovaTarg, Novo Nordisk, Sanofi, Tolerion, and vTv Therapeutics; personal compensation for consultation from Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, CeQur, Cirius Therapeutics, Corcept Therapeutics, Eli Lilly, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego, Sanofi, Stability Health, Terns, Valo, and Zealand Pharma; and stock or stock options in Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, and Stability Health. JMN was supported by a grant (K23HL133604) from the National Heart, Lung, and Blood Institute of the NIH. DJO was supported by the Institute for Engineering in Medicine, University of Minnesota Office of Academic and Clinical Affairs COVID-19 Rapid Response Grant, the Earl E Bakken Professorship for Engineering in Medicine, and by grants (U54 CA210190 and P01 CA254849) from the National Cancer Institute of the NIH. TAM was supported in part by the Medtronic Faculty Fellowship. DML receives funding from NIH RECOVER (OT2HL161847). LKS was supported by NIH grants (18X107CF6 and 18X107CF5) through a contract with Leidos Biomedical and by grants from the National Heart, Lung, and Blood Institute of the NIH (T32HL129956), and the NIH (R01LM012982 and R21LM012744). MAP receives grants from the Bill &amp; Melinda Gates Foundation (INV-017069), Minnesota Partnership for Biotechnology and Medical Genomics (00086722), and the National Heart, Lung, and Blood Institute of the NIH (OT2HL156812); and consulting fees from Opticyte and Cytovale. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atwater</LastName><ForeName>Riannon C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avula</LastName><ForeName>Nandini</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckman</LastName><ForeName>Kenny B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh K</ForeName><Initials>HK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brea</LastName><ForeName>Jannis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broedlow</LastName><ForeName>Courtney A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campora</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Challa</LastName><ForeName>Anup</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christensen</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connelly</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Datta</LastName><ForeName>Srijani</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deng</LastName><ForeName>Nikita</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunn</LastName><ForeName>Alex T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairbairn</LastName><ForeName>Faith M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fraser</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fricton</LastName><ForeName>Regina D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Gwen</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagen</LastName><ForeName>Aubrey A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendrickson</LastName><ForeName>Audrey F</ForeName><Initials>AF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingraham</LastName><ForeName>Nicholas E</ForeName><Initials>NE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeng</LastName><ForeName>Arthur C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Darrell M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuehl</LastName><ForeName>Erik A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaBar</LastName><ForeName>Derek D</ForeName><Initials>DD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindberg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luke</LastName><ForeName>Darlette G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Machicado</LastName><ForeName>Rosario</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohamud</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ngonyama</LastName><ForeName>Rumbidzai</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odde</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parrens</LastName><ForeName>Elliott</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parra</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proper</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pullen</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Via</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>Neha V</ForeName><Initials>NV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>Naveen</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rypka</LastName><ForeName>Katelyn J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saveraid</LastName><ForeName>Hanna G</ForeName><Initials>HG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seloadji</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shahriar</LastName><ForeName>Arman</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siegart</LastName><ForeName>Jamie L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lianne K</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simmons</LastName><ForeName>Lucas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinelli</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Palak</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stauffer</LastName><ForeName>Maxwell T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tople</LastName><ForeName>Tannon L</ForeName><Initials>TL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tordsen</LastName><ForeName>Walker J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>Ray Hb</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Beiqing</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaman</LastName><ForeName>Adnin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zolik</LastName><ForeName>Madeline R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zinkl</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>11</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37302406</ArticleId><ArticleId IdType="mid">NIHMS2003365</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pii">S1473-3099(23)00299-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html (accessed
Dec 11, 2022).</Citation></Reference><Reference><Citation>Yang C, Zhao H, Tebbutt SJ. A glimpse into long COVID and symptoms. Lancet Respir Med 2022; 10: e81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187332</ArticleId><ArticleId IdType="pubmed">35697054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum 2022; 3: e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention. Long COVID. 2022. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm (accessed
Dec 12, 2022).</Citation></Reference><Reference><Citation>Pfaff ER, Girvin AT, Bennett TD, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health 2022; 4: e532&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med 2022; 387: 599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen SCJ, Miljanic S, Tabbara N, et al. Inclusion of pregnant and breastfeeding women in nonobstetrical randomized controlled trials. Am J Obstet Gynecol MFM 2022; 4: 100700.</Citation><ArticleIdList><ArticleId IdType="pubmed">35914736</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Soto Conti CP, Gunier RB, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet 2023; 401: 447&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9910845</ArticleId><ArticleId IdType="pubmed">36669520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalafat E, Sukur YE, Abdi A, Thilaganathan B, Khalil A. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. Ultrasound Obstet Gynecol 2018; 52: 706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">29749110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W Mass weighted urn design&#x2014;a new randomization algorithm for unequal allocations. Contemp Clin Trials 2015; 43: 209&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522356</ArticleId><ArticleId IdType="pubmed">26091947</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Brown M, Hilaire DS, Wright A. Healthcare provider attitudes towards the problem list in an electronic health record: a mixed-methods qualitative study. BMC Med Inform Decis Mak 2012; 12: 127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534408</ArticleId><ArticleId IdType="pubmed">23140312</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy SF, White IR, Nunn AJ, Hayes R, Wang D, Harrison TS. Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: clear guidance is needed. Contemp Clin Trials 2022; 113: 106656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844584</ArticleId><ArticleId IdType="pubmed">34906747</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker RA, Weir CJ. Non-adjustment for multiple testing in multi-arm trials of distinct treatments: rationale and justification. Clin Trials 2020; 17: 562&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534018</ArticleId><ArticleId IdType="pubmed">32666813</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JE, Cook NR, Lee I-M, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380: 33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425757</ArticleId><ArticleId IdType="pubmed">30415629</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019; 380: 23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392053</ArticleId><ArticleId IdType="pubmed">30415637</ArticleId></ArticleIdList></Reference><Reference><Citation>Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med 2021; 9: 1427&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8555973</ArticleId><ArticleId IdType="pubmed">34756178</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ 2016; 352: i1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">27121591</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Stone GW. The primary outcome fails&#x2014;what next? N Engl J Med 2016; 375: 861&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27579636</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Nov
11, 2021. https://www.nice.org.uk/guidance/ng188 (accessed
April 12, 2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102&#x2013;07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022; 10: e42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C, Cervantes-Luevano K, Aguirre-S&#xe1;nchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, phase IIb clinical trial. Biomed Pharmacother 2022; 152: 113223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, et al. Long COVID: where we stand and challenges ahead. Cell Death Differ 2022; 29: 1891&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv 2020; published online June 16. 10.1101/2020.05.22.111237 (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.22.111237</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam BS, Morris RS, Bramante CT, et al. mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses. J Med Virol 2021; 93: 1843&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159020</ArticleId><ArticleId IdType="pubmed">33314219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020; 583: 459&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res 2022; 323: 199010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller MA, Sharma Y, Dupee Z, et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight 2021; 6: e148003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492301</ArticleId><ArticleId IdType="pubmed">34357881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun T, Liu J, Xie C, Yang J, Zhao L, Yang J. Metformin attenuates diabetic renal injury via the AMPK-autophagy axis. Exp Ther Med 2021; 21: 578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027752</ArticleId><ArticleId IdType="pubmed">33850550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Liu Y, Huang Z, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ 2022; 29: 1240&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177730</ArticleId><ArticleId IdType="pubmed">34997207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Han Y, Yang L, et al. SARS-CoV-2 infection causes dopaminergic neuron senescence. Res Sq 2021: published online May 21. 10.21203/rs.3.rs-513461/v1 (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-513461/v1</ArticleId><ArticleId IdType="pmc">PMC10843182</ArticleId><ArticleId IdType="pubmed">38237586</ArticleId></ArticleIdList></Reference><Reference><Citation>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 2010: CD002967.</Citation><ArticleIdList><ArticleId IdType="pubmed">20091535</ArticleId></ArticleIdList></Reference><Reference><Citation>Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6: 395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">23508758</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg LE, Jing Y, Penland RC, et al. Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. Diabetes Obes Metab 2021; 23: 1101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33394543</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al. Metformin in the management of childhood obesity: a randomized control trial. Child Obes 2018; 14: 553&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">30070925</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LL, Umpierrez GE, Inzucchi SE. Management of hyperglycemia in hospitalized, non-critically ill adults. N Engl J Med 2022; 387: 1040&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">36103419</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz KM, Marroquin OC, Zenati MS, et al. Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes. JAMA Surg 2020; 155: e200416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142798</ArticleId><ArticleId IdType="pubmed">32267474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates S Statistical significance and clinical evidence. Lancet Oncol 2020; 21: e118.</Citation><ArticleIdList><ArticleId IdType="pubmed">32135102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>